Pfizer has initiated Phase 1 clinical tests of PF-07304814, a small molecule that could be used in the fight against SARS-CoV-2, which causes COVID-19. The drug targets the 3CL protease, an enzyme that allows the virus to multiply. If approved, PF-07304814 would be the first antiviral drug to target this protein. With 21 strategically located global depots, Yourway can fully support global trial needs around the world.